04.02.2019
Resaphene Suisse AG was informed after the hearing at the European Patent Office about the forthcoming grant of the patent. As a next step, the Board also expects to complete the patent process in the US.
In February 2019, management will introduce tinnitus therapy in the US and drive expansion there. A decision whether a separate national company is founded there or if sales partners are used has not yet fallen.
Back